Guselkumab provides durable improvement across psoriatic arthritis disease domains : post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: Evaluate long-term guselkumab effectiveness across Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-recognised domains/related conditions of psoriatic arthritis (PsA).
METHODS: Post hoc analyses used data from DISCOVER-2 (NCT03158285) biologic/Janus-kinase inhibitor-naïve participants with active PsA (≥5 swollen/≥5 tender joints, C-reactive protein ≥0.6 mg/dL), randomised (1:1:1) to guselkumab every 4 or 8 weeks (Q4W/Q8W) or placebo with crossover to guselkumab. Outcomes aligned with key GRAPPA-recognised domains of overall disease activity, peripheral arthritis, axial disease, enthesitis/dactylitis and skin psoriasis (nail psoriasis was not evaluated). PsA-related conditions (inflammatory bowel disease (IBD)/uveitis) were assessed via adverse events through W112. Least squares mean changes from baseline through W100 in continuous outcomes employed repeated measures mixed-effects models adjusting for baseline scores. Binary measure response rates were determined with non-responder imputation for missing data.
RESULTS: 442/493 (90%) of guselkumab-randomised patients completed treatment through W100. Following early reductions in disease activity with guselkumab, durable improvements were observed across key PsA domains (swollen/tender joints, psoriasis, spinal pain, enthesitis/dactylitis) through W100. Response rates of therapeutically relevant targets generally increased through W100 with guselkumab Q4W/Q8W: Disease Activity Index for PsA low disease activity (LDA) 62%/59%, enthesitis resolution 61%/70%, dactylitis resolution 72%/83%, 100% improvement in Psoriasis Area and Severity Index 59%/53%, Psoriatic Arthritis Disease Activity Score LDA 51%/49% and minimal disease activity 38%/40%. Through W112, no cases of IBD developed among guselkumab-randomised patients and one case of uveitis was reported.
CONCLUSION: In biologic-naïve patients with active PsA, guselkumab provided early and durable improvements in key GRAPPA-recognised domains through 2 years, with substantial proportions achieving important treatment targets.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
---|---|
Enthalten in: |
RMD open - 10(2024), 1 vom: 26. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Coates, Laura C [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 28.03.2024 Date Revised 29.03.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1136/rmdopen-2023-003977 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370211685 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370211685 | ||
003 | DE-627 | ||
005 | 20240330001449.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240328s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1136/rmdopen-2023-003977 |2 doi | |
028 | 5 | 2 | |a pubmed24n1355.xml |
035 | |a (DE-627)NLM370211685 | ||
035 | |a (NLM)38531621 | ||
035 | |a (PII)e003977 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Coates, Laura C |e verfasserin |4 aut | |
245 | 1 | 0 | |a Guselkumab provides durable improvement across psoriatic arthritis disease domains |b post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.03.2024 | ||
500 | |a Date Revised 29.03.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
520 | |a OBJECTIVE: Evaluate long-term guselkumab effectiveness across Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-recognised domains/related conditions of psoriatic arthritis (PsA) | ||
520 | |a METHODS: Post hoc analyses used data from DISCOVER-2 (NCT03158285) biologic/Janus-kinase inhibitor-naïve participants with active PsA (≥5 swollen/≥5 tender joints, C-reactive protein ≥0.6 mg/dL), randomised (1:1:1) to guselkumab every 4 or 8 weeks (Q4W/Q8W) or placebo with crossover to guselkumab. Outcomes aligned with key GRAPPA-recognised domains of overall disease activity, peripheral arthritis, axial disease, enthesitis/dactylitis and skin psoriasis (nail psoriasis was not evaluated). PsA-related conditions (inflammatory bowel disease (IBD)/uveitis) were assessed via adverse events through W112. Least squares mean changes from baseline through W100 in continuous outcomes employed repeated measures mixed-effects models adjusting for baseline scores. Binary measure response rates were determined with non-responder imputation for missing data | ||
520 | |a RESULTS: 442/493 (90%) of guselkumab-randomised patients completed treatment through W100. Following early reductions in disease activity with guselkumab, durable improvements were observed across key PsA domains (swollen/tender joints, psoriasis, spinal pain, enthesitis/dactylitis) through W100. Response rates of therapeutically relevant targets generally increased through W100 with guselkumab Q4W/Q8W: Disease Activity Index for PsA low disease activity (LDA) 62%/59%, enthesitis resolution 61%/70%, dactylitis resolution 72%/83%, 100% improvement in Psoriasis Area and Severity Index 59%/53%, Psoriatic Arthritis Disease Activity Score LDA 51%/49% and minimal disease activity 38%/40%. Through W112, no cases of IBD developed among guselkumab-randomised patients and one case of uveitis was reported | ||
520 | |a CONCLUSION: In biologic-naïve patients with active PsA, guselkumab provided early and durable improvements in key GRAPPA-recognised domains through 2 years, with substantial proportions achieving important treatment targets | ||
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Clinical Trial, Phase III | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Biological Therapy | |
650 | 4 | |a Psoriatic Arthritis | |
650 | 4 | |a Severity of Illness Index | |
650 | 7 | |a guselkumab |2 NLM | |
650 | 7 | |a 089658A12D |2 NLM | |
650 | 7 | |a Biological Products |2 NLM | |
650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
700 | 1 | |a Gossec, Laure |e verfasserin |4 aut | |
700 | 1 | |a Zimmermann, Miriam |e verfasserin |4 aut | |
700 | 1 | |a Shawi, May |e verfasserin |4 aut | |
700 | 1 | |a Rampakakis, Emmanouil |e verfasserin |4 aut | |
700 | 1 | |a Shiff, Natalie J |e verfasserin |4 aut | |
700 | 1 | |a Kollmeier, Alexa P |e verfasserin |4 aut | |
700 | 1 | |a Xu, Xie L |e verfasserin |4 aut | |
700 | 1 | |a Nash, Peter |e verfasserin |4 aut | |
700 | 1 | |a Mease, Philip J |e verfasserin |4 aut | |
700 | 1 | |a Helliwell, Philip S |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t RMD open |d 2015 |g 10(2024), 1 vom: 26. März |w (DE-627)NLM254089658 |x 2056-5933 |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2024 |g number:1 |g day:26 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1136/rmdopen-2023-003977 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 10 |j 2024 |e 1 |b 26 |c 03 |